inclusion criteria: 1. participants 18 through 64 years of age, inclusive, at the time of consent. 2. are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3. adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. 4. have received 3 prior doses of 30 µg bnt162b2, with the third dose being at least 90 days before visit 1 (day 1). documented confirmation of prior bnt162b2 receipt must be obtained prior to randomization. 5. capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the icd and in this protocol.

inclusion criteria: 1. participants 18 through 64 years of age, inclusive, at the time of consent. 2. are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3. adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. 4. have received 3 prior doses of 30 µg bnt162b2, with the third dose being at least 90 days before visit 1 (day 1). documented confirmation of prior bnt162b2 receipt must be obtained prior to randomization. 5. capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the icd and in this protocol.

inclusion criteria: participants 18 through 64 years of age, inclusive, at the time of consent. are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. have received 3 prior doses of 30 µg bnt162b2, with the third dose being at least 90 days before visit 1 (day 1). documented confirmation of prior bnt162b2 receipt must be obtained prior to randomization. capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the icd and in this protocol.

inclusion criteria: participants 18 through 64 years of age, inclusive, at the time of consent. are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. have received 3 prior doses of 30 µg bnt162b2, with the third dose being at least 90 days before visit 1 (day 1). documented confirmation of prior bnt162b2 receipt must be obtained prior to randomization. capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the icd and in this protocol.